- Nakatomi K, Soda H, Kitazaki T, Nakano H, Uchida K, Urabe S, Nakamura Y, Hayashi T, Tsukamoto K, Kohno S. Long-term survival in three patients with metastatic non-small cell lung cancer treated with gefitinib. Lung Cancer 52(2): 253-255, 2006
- Nakatomi K, Yoshikawa M, Oka M, Ikegami Y, Hayasaka S, Sano K, Shiozawa K, Kawabata S, Soda H, Ishikawa T, Tanabe S, Kohno S. Transport of 7-ethyl-10-hydroxycamptothecin （SN-38） by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun. 9; 288(4): 827-832, 2001
- Tomita H, Yamada K, Ghadami M, Ogura T, Yanai Y, Nakatomi K, Sadamatsu M, Masui A, Kato N, Niikawa N. Mapping of the wet/dry earwax locus to the pericentromeric region of chromosome 16. Lancet. 8; 359(9322): 2000-2, 2002
- Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H, Kohno S. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 65(4): 1541-1546, 2005.
- Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J, Nakatomi K, Nakamura Y, Doi S, Kitazaki T, Mizuta Y, Murase K, Yoshida H, Ross DD, Kohno S. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. Int J Cancer 108(1): 146-151, 2004.
|
|
